Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 5/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4388271 | 0.99 | IDO1 (0.51) | IDO1TACR1HTR2CHTR2BHTR6 | |
| SCHEMBL4410979 | 0.78 | MEN1 (0.48) | IDO1MAOBMMP1MMP12 | |
| SCHEMBL2312874 | 0.78 | NPC1 (0.51) | TACR1HTR2CHTR2BSLC6A4SLC6A2 | |
| SCHEMBL4382904 | 0.77 | LMNA (0.45) | IDO1TACR1MAOBALDH1A1 | |
| Hydrochloric Acid SCHEMBL4391643 | 0.76 | NPC1 (0.50) | TACR1HTR2CHTR2BSLC6A4SLC6A2 | |
| SCHEMBL4385367 | 0.75 | HTT (0.51) | ALDH1A1 | |
| SCHEMBL4388294 | 0.75 | MEN1 (0.51) | IDO1MAOBALDH1A1 | |
| SCHEMBL17986313 | 0.75 | IDO1 (0.64) | IDO1HTR2CHTR2BMAOBTAAR1 | |
| SCHEMBL4391011 | 0.74 | LMNA (0.54) | ALDH1A1 | |
| SCHEMBL4379552 | 0.74 | LMNA (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | IDO1 305/4885TACR1 381/4885HTR2C 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.